Wang SM, Zhu J, Pan LF, Liu YK. Inhibitory effect of dimeric β peptide on the recurrence and metastasis of hepatocellular carcinoma in vitro and in mice. World J Gastroenterol 2008; 14(19): 3054-3058
Corresponding Author of This Article
Professor Jun Zhu, Department of Pharmacy, Shanghai Chest Hospital, Shanghai 200031, China. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 21, 2008; 14(19): 3054-3058 Published online May 21, 2008. doi: 10.3748/wjg.14.3054
Inhibitory effect of dimeric β peptide on the recurrence and metastasis of hepatocellular carcinoma in vitro and in mice
Song-Mei Wang, Jun Zhu, Luan-Feng Pan, Yin-Kun Liu
Song-Mei Wang, Luan-Feng Pan, Laboratory of Molecular Biology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Jun Zhu, Department of Pharmacy, Shanghai Chest Hospital, Shanghai 200031, China
Yin-Kun Liu, Liver Cancer Institute, Fudan University, Shanghai 200032, China
ORCID number: $[AuthorORCIDs]
Correspondence to: Professor Jun Zhu, Department of Pharmacy, Shanghai Chest Hospital, Shanghai 200031, China. email@example.com
Received: June 21, 2007 Revised: March 25, 2008 Published online: May 21, 2008
AIM: To block the adhesion of tumor cells to the extracellular matrix, and prevent tumor metastasis and recurrence, the dimer of the β peptide (DLYYLMDLSYSMKGGDLYYLMDLSYSMK, β2) was designed and synthesized and its anti-adhesion and anti-invasion effects on hepatocellular carcinoma cells were assessed. Additionally, its influence on the metastasis and recurrence of mouse hepatocellular carcinoma was measured.
METHODS: The anti-adhesion effect of β2 on the highly metastatic hepatocellular carcinoma cell line HCCLM6 cells and fibronectin (FN) was assayed by the MTT assay. The inhibition of invasion of HCCLM6 cells by β2 was observed using a Transwell (modified Boyden chamber) and matrigel. Using the hepatocellular carcinoma metastasis model and LCI-D20 nude mice, the influence of β2 on the metastasis and recurrence of hepatocellular carcinoma after early resection was investigated.
RESULTS: HCCLM6 cells co-incubated with 100 &mgr;mol/L, 50 &mgr;mol/L, 20 &mgr;mol/L or 10 &mgr;mol/L β2 for 3 h showed an obvious decrease in adhesion to FN. The adhesion inhibition ratios were 11.8%, 21.7%, 29.6% and 48.7%, respectively. Additionally, HCCLM6 cells cultured with 100 &mgr;mol/L β2 had a dramatic decrease in cell invasion. β2 was also observed to inhibit the incisal edge recurrence and the distant metastasis of nude mice hepatocellular carcinoma after early resection (P < 0.05).
CONCLUSION: The β2 peptide can specifically block the adhesion and invasion of HCCLM6 cells, and can inhibit HCC recurrence and metastasis of LCI-D20 model posthepatectomy in vivo. Thus, β2 should be further studied as a new anti-tumor drug.
Citation: Wang SM, Zhu J, Pan LF, Liu YK. Inhibitory effect of dimeric β peptide on the recurrence and metastasis of hepatocellular carcinoma in vitro and in mice. World J Gastroenterol 2008; 14(19): 3054-3058
Despite significant advances in the treatment of human hepatocellular carcinoma (HCC) and the prevention of postoperative metastasis, the 5-year postoperative recurrence rate of HCC is still very high. Many efforts have been made to develop a more efficient treatment to inhibit and prevent tumor metastasis, as the recurrence and metastasis of HCC is still a large problem in clinical practice. It is well known that the metastatic process is very complex, including tumor cells dissociating from the primary locus, invading the surrounding tissue, entering and extravasating from the circulation, and growing in distant organs. During this process, cell adhesion is one of the most important events. Many studies have been focused on the synthesized anti-adhesion peptides[6–8]. However, the application of these short peptides is limited due to their short half-life and high dosage required. To prolong the peptide's half-life, the polymer and a derivative of synthesized peptides were designed[9–11]. The anti-tumor metastasis effect of the repeat sequence of synthesized peptides was stronger than that of non-repeat peptides.
Integrins are a family of adhesion molecules located on cells and in the extracellular matrix. The expression level of integrins is related closely to a cell’s migration ability. The anti-adhesion peptide β (DLYYLMDLSYSMK, β1) was designed by Liu et al, according to the conserved sequence of the integrin α and β unit. This peptide can block the interaction between tumor cells and the extracellular matrix and can also inhibit intrahepatic and pulmonary metastases after carcinosectomy in a nude mouse model with human HCC of high metastatic potential (LCI-D20)[17–21]. On the basis of these studies, here we have designed and synthesized the dimeric peptide β (β2). The effects of β2 on the adhesion of human liver cancer cell line HCCLM6 cells to fibronectin (FN), the invasion of HCCLM6 cells to reconstituted basement membrane, as well as liver cancer recurrence and metastasis after hepatectomy in a nude mouse model were investigated.
MATERIALS AND METHODS
The highly metastatic hepatocellular carcinoma cell line HCCLM6, initially established and preserved by the Liver Cancer Institute, Fudan University, was cultured in Dulbecco’s modified eagle’s medium (DMEM, Gibco, UK), supplemented with 10% fetal bovine serum, 100 U/mL penicillin and grown at 37°C under an atmosphere of 5% CO2. The medium was replenished every three days to maintain cell growth.
Coating the 96 well high bind microplate with FN
Ten &mgr;g/mL FN (Sigma, USA) solution (containing 10 &mgr;g/mL FN, 20 mmol/L Tris-Cl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L MgCl2, 1 mmol/L CaCl2, 1 mmol/L MnCl2) was added to a 96-well high bind microplate (Corning, USA) (100 &mgr;L per well), and allowed to incubate at 4°C overnight. The plate was then incubated with blocking buffer (10 mmol/L Hepes, pH 7.4, 140 mmol/L NaCl, 5.4 mmol/L KCl, 5.56 mmol/L glucose, 3% BSA, 1 mmol/L MgCl2, 2 mmol/L CaCl2, 1 mmol/L MnCl2) at 37°C for 2 h and air dried for further use.
Cell adhesion assay
β2 peptide was designed in our laboratory using the sequence DLYYLMDLSYSMKGGDLYYLMDLSYSMK. The peptide was synthesized by Shanghai Sangon Bioengineering Company. 100 &mgr;L of a HCCLM6 suspension (2 × 105/mL) was plated in each well of an FN coated 96-well high bind microplate. 100 &mgr;L DMEM medium containing β2 at a concentration of 200 &mgr;mol/L, 100 &mgr;mol/L, 40 &mgr;mol/L or 20 &mgr;mol/L was added to the cells concomitantly. The same volume of cell culture medium in place of β2 was added to the control group. 200 &mgr;L of cell culture medium only was added in the plate for the blank group. The assay was conducted in quintuplicate for each sample. After incubation for 3 h at 37°C, under an atmosphere of 5% CO2, the unattached cells were gently washed away with HANKS buffer. The attached cell number in each well was measured by MTT. The inhibition rate of β2 on cell adhesion to FN was calculated with the following equation: Cell adhesion inhibitory rate = (average OD of control well-average OD of β2-treated well)/(average OD of control well-average OD of blank well) × 100%
The number of attached cells in each well was examined by the MTT assay, as previously described, and quantified by a micro-titer plate reader (Amersham, USA). Briefly, after incubation for 3 h at 37°C in 5% CO2, the unattached cells were removed by gentle washing with HANKS buffer. 100 &mgr;L DMEM and 20 &mgr;L MTT (5 mg/mL) (Sigma, USA) were added to each well. After incubation at 37°C for 4 h, the medium was discarded. 200 &mgr;L of 0.04 mol/L hydrochloric acid in isopropanol was added to each well. The amount of MTT formazan product, which reflects the number of cells adhering to FN, was determined by measuring absorbance with a microplate reader at a test wavelength of 570 nm and a reference wavelength of 630 nm.
Invasion assays were performed as described previously. Briefly, the upper portion of Transwell chambers (Corning, USA) were coated with 75 &mgr;L of Matrigel (BD, USA) diluted 1:10 in serum-free DMEM and incubated at 37°C for 2 h. The supernatants of HCCLM6 cells containing DMEM with 10% FCS were harvested after the cells had grown to confluence, and after adding FN at a final concentration of 5 &mgr;g/mL, resulting in conditioned medium. The trypsinized cells were harvested and diluted to a 2 × 106/mL cell suspension with serum-free DMEM. 100 &mgr;L of the cell suspension and 100 &mgr;L of 200 &mgr;mol/L β2 peptides in serum-free DMEM or serum-free DMEM only as a control were added in the upper chambers. Concurrently, 600 &mgr;L of conditioned medium was added to the bottom chamber of the Transwell plate. After incubation at 37°C for 48 h under a 5% CO2 atmosphere, the non-invading cells and the gel were gently removed from the upper chamber with cotton-tipped swabs. Cells were rinsed with PBS, and the cells on the filters were fixed with Formaldehyde and stained in Giemsa staining solution for 30 min. The number of invaded cells on the filters was counted in 5 randomly selected high-powered (× 200) fields per filter under a microscope (Leica, Switzerland). Invasion inhibitory rate was expressed as the following equation: Invasion inhibitory rate = [1 - (invaded cell number in β2 chamber/invaded cell number in control chamber)] × 100%.
Animal model and treatment
Twelve 5-wk-old male nude mice (BALB/cA) weighing 17-20 g were obtained from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The nude mouse model of human hepatocellular carcinoma with high metastatic potential (LCI-D20), which was established in Zhongshan Hospital Liver Cancer Institute, Fudan University, was used in this study. A tumor block of LCI-D20 nude mice human liver cancer metastasis model was implanted into the left lobe of the nude mouse liver as described previously. Briefly, a left upper abdominal transverse incision was made under anesthesia; the left lobe of the liver was exposed and a part of the liver surface was mechanically injured with scissors. Next, a tumor block of 0.2 cm × 0.2 cm × 0.2 cm was fixed within the liver tissue. After the operation, mice were kept in laminar-flow cabinets under specific-pathogen-free conditions and given free access to mouse chow. Liver cancer early resection was performed 0.2 cm from the edge of the cancer at day 10 after implantation, prior to metastasis. At day 1 after resection, the animals were subcutaneously administrated 100 &mgr;L of 1 mg/mL of β2 or NS as a control every other day for 10 doses. Mice were harvested at day 55 postimplantation, and lungs were fixed in 10% formalin, embedded in paraffin, cut into 5 &mgr;m slides and metastatic nodes were observed and counted under a microscope. If recurrence of the incisal margin of cancer was found, the lesion would be resected and weighed.
All of the animal experiments were conducted in strict accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.
All data were entered into Excel spreadsheets (Excel, Microsoft, Seattle, USA). We used the SAS program (SAS Institute Inc., Cary, NC, USA) for statistical analysis. Comparisons for dimensional outcomes employed the Student’s t-test, or the Mann Whitney U test when the data were not normally distributed. Values of P < 0.05 in a two-tailed fashion were considered to be statistically significant.
The inhibitory effect of β2 on the adhesion of HCCLM6 cells to FN
The inhibitory effect of β2 on the adhesion of HCCLM6 cells to FN is shown in Figure 1. HCCLM6 cells co-incubated with 100 &mgr;mol/L, 50 &mgr;mol/L, 20 &mgr;mol/L and 10 &mgr;mol/L β2 for 3 h led to an obvious decrease in cellular adhesion. The adhesion inhibition ratios were 11.8%, 21.7%, 29.6% and 48.7%, respectively. This observation indicates that β2 is able to inhibit the adhesion of HCCLM6 cells to FN, and thus β2 might obstruct the invasion of HCC cells to paratumor liver parenchyma.
Figure 1 The inhibitory effect of β2 on the adhesion of HCCLM6 cells to fibronectin (n = 5).
The inhibitory effect of β2 on the invasion ability of HCCLM6 cells
After incubation with 100 &mgr;mol/L β2, the number of invaded HCCLM6 cells was decreased. The inhibitory rate was 36.8% (Table 1). Thus, β2 might block HCC cells from invading the surrounding tissue and entering and extravasating from the circulation in vivo.
Table 1 The inhibitory effects of β2 on the invasion ability of HCCLM6 cells (n = 5).
Mean of invaded cell (SD)
Invasion inhibitory rate (%)
The influence of β2 on the intrahepatic recurrence of the LCI-D20 model after early resection
On the 10th d post-tumor-implantation, LCI-D20 tumors were resected, and β2 or the same volume of saline was subcutaneously injected. On day 55, mice were sacrificed to check for intrahepatic recurrence. The recurrent tumor was located around the incisal margins. Compared with the control group, the weight of the intrahepatic recurrent tumor of the β2 group was markedly decreased and statistically significant. There were 4 (4/6) mice with intrahepatic recurrent tumor in the β2 group, while there were 6 (6/6) mice with an intrahepatic recurrent tumor in the control group (Figure 1 and Table 2). These results indicate that β2 have inhibitory effects on tumor recurrence in the incisal margin.
Table 2 Liver cancer recurrences in incisal margins in nude mouse models after early resection.
The inhibitory effects of β2 on metastasis of liver cancer in nude mouse models after early resection
On the 55th day after tumor implantation, the number of metastatic nodes was calculated under a microscope. The result showed that there were fewer metastatic nodes in the β2 treatment group compared to the control group, and there was a statistical difference between the β2 group and the control group. Furthermore, all of the 6 mice in the control group (6/6) had metastatic nodes, but only 4 (4/6) mice had metastatic nodes in the β2 group. These results indicate that β2 have a significant preventive and therapeutic effect on the metastasis of liver cancer (Table 3).
Table 3 The lung metastasis in liver cancer nude mouse models after early resection.
The adhesion molecules on the surface of both tumor cells and endothelial cells are associated with tumor metastasis and recurrence. Blocking the interaction between tumor cell adhesion molecules and their ligands is a major target in the prevention of cancer metastasis. Many studies have focused on the synthesized anti-adhesion peptides. One such peptide is RGD, derived from the common conserved sequence of the main matrix proteins such as fibronectin, collagen and fibrinogen. A second peptide is YIGSR, which originated from the basement membrane protein laminin. The third peptide is EILDV, which stemmed from the core sequence of fibronectin. The application of these short peptides was limited due to their short half-life, the ease with which they are degraded and the requirement for a high dosage. To prolong the peptides’ half-life, the polymer and derivative of synthesized peptides were designed. The anti-tumor metastatic effect of repeat sequence of synthesized peptides was stronger compared to non-repeat peptides. The more times the sequence is repeated, the stronger the anti-metastasis effect is.
FN is an important cell adhesion molecule in the extracellular matrix. It mediates cell adhesion and migration, and plays a significant role in tumor invasion and metastasis. Assaying FN adhesion to tumor cells is a method commonly used for studying tumor cell metastasis. In this study, the extracellular matrix was simulated by coating cell culture plates with FN, after which the inhibitory effects of β2 peptide on FN adhesion to liver cancer cells were investigated. The results demonstrated that after co-culturing the peptides with HCCLM6 cells for 3 h, a distinct and specific inhibitory effect of β2 peptide on FN adhesion to tumor cells was observed.
Tumor cells must penetrate the basement membrane for at least three times during metastasis; i.e. dislodging from the original site, entering blood circulation, and migrating from blood flow into remote sites. Matrigel, used as a basement membrane matrix, is produced from mouse Engelbreth-Holm-Swarm sarcoma rich in extracellular matrix protein. The artificial basement membrane is plated on a Millipore filter in Transwell culture chambers, and forms a membrane structure similar to natural basement membrane. Invasive, metastatic tumor cells can penetrate the membrane under the induction of chemotactics, simulating tumor cells’ invasion of the basement membrane in vivo. The results indicated that β2 exerted significant inhibitory effects on the invasion of HCCLM6 cells.
Metastasis and recurrence of liver cancer is a major determinant for the prognosis and long-term survival of liver cancer patients. Polypeptide therapy is a newly developed treatment for tumors, but its clinical application is restricted by the degradation of these peptides. β peptides can inhibit the metastasis and recurrence of human liver cancer in nude mouse models after early excision, and can also block the recurrence of cancer at the incisal margins.
The β peptide blocked tumor cell adhesion to FN through two possible mechanisms. First, the β peptide took up the integrin binding site competently through binding to the RGD sequence of the matrix protein. Next, the β peptide also interacted with integrin because the β peptide was designed according to the conserved sequence of the integrin α and β unit.
Taken together, these cell and animal studies demonstrated that the β2 peptide can prevent and treat liver cancer adhesion and metastasis and recurrence. Therefore, the β peptide is worthy of further investigation, as it is a potential drug for blocking tumor metastasis and recurrence.
Despite significant advances in the treatment of human hepatocellular carcinoma (HCC), metastasis and recurrence remain the main obstacles for HCC patients gaining a better outcome and long-term survival. It is well known that during the metastatic process, cell adhesion is one of the most important events. The adhesion molecules on the surface of both tumor cells and endothelial cells are associated with tumor metastasis and recurrence. So, blocking the interaction between tumor cell adhesion molecules and their ligands has become a major target in prevention cancer metastasis.
To prevent tumor metastasis and recurrence through inhibiting the adhesion of tumor cells, many studies have focused on the synthesized anti-adhesion peptides such as RGD, YIGSR and EILDV. These peptides are derived from the common conserved sequence of the main matrix proteins such as fibronectin, collagen, fibrinogen and laminin. Liu et al designed a new anti-adhesion peptide β (DLYYLMDLSYSMK, β1) according to the conserved sequence of the α and β unit of integrins. These peptides can inhibit the adhesion of tumor cells and cancer metastasis and recurrence. But their application is limited due to the short half-life and high dosage required.
Innovations and breakthroughs
On the basis of Liu’s study, to prolong the peptide’s half-life, the dimmer of β peptide (DLYYLMDLSYSMKGGDLYYLMDLSYSMK, β2) was designed and synthesized and the anti-adhesion and anti-invasion effect of it on hepatocellular carcinoma cells, as well as it’s influence to the metastasis and recurrence of mouse hepatocellular carcinoma were measured. The result showed that β2 can inhibit the adhesion of HCCLM6 cells to FN in dose-effect manner. And the number of invaded HCCLM6 cells was decreased when incubated together with 100 &mgr;mol/L β2. Compared with the control group, the weight of the intrahepatic recurrent tumor and the number of metastatic nodes in lung of the β2 group were markedly decreased.
β2 might obstruct the invasion of HCC cells to paratumor liver parenchyma and block HCC cells from invading the surrounding tissue and entering and extravasating from the circulation in vivo. In addition, β2 have inhibitory effects on tumor recurrence in the incisal margin and a significant preventive and therapeutic effect on the metastasis of liver cancer. Taken together, these cell and animal studies demonstrated that the β2 peptide can prevent and treat liver cancer adhesion, metastasis and recurrence.
On the basis of previous work, the β2 peptide (DLYYLMDLSYSMKGGDLYYLMDLSYSMK, β2) was designed and synthesized. After co-culturing with HCCLM6 cells for 3 h, a distinct and specific inhibitory effect of β2 peptide on FN adhesion to tumor cells was observed. And also β2 showed significant inhibitory effects on the invasion of HCCLM6 cells. Furthermore, β2 peptides can inhibit the metastasis and recurrence of human liver cancer in nude mouse models after early excision, and can also block the recurrence of cancer at the incisal margins. These results indicate that β2 have a significant preventive and therapeutic effect on the metastasis of liver cancer.
Supported by National High-Tech Program of China, No. 2001AA215411 and No. 2004AA215201, and Shanghai Science and Technology Developing Program, No. 024319212
Fang WQ, Li SP, Zhang CQ, Xu L, Shi M, Chen MS, Li JQ. [Prophylaxis and clinical treatment for surgical margin recurrence of small primary hepatocellular carcinoma].Ai Zheng. 2005;24:834-836.
Lee WC, Jeng LB, Chen MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma.Br J Surg. 2002;89:311-316.
Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.Cell. 1991;64:327-336.
Chu XY, Chen LB. Cellular adhesive molecular and the invasion and metastasis of neoplasm.Yixue Yanjiusheng Xuebao. 2000;13:42-45.
Li FH. The inhibitory effect of bioactive peptides on neoplasm metastasis.Kouqiang Hemian Waike Zazhi. 1999;9:231-234.
Liu LY, Chen ZY, Zhao TH. Investigations of a peptide with RGD and YIGSR fragments: synthesis and its anti-tumor invasion activities.Zhongguo Xinyao Zazhi. 2005;14:729-731.
Saiki I, Yoneda J, Kobayashi H, Igarashi Y, Komazawa H, Ishizaki Y, Kato I, Azuma I. Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs.Jpn J Cancer Res. 1993;84:326-335.
Zhang HQ, Shinohara H, Gu N, Sasaki H, Sisido M. Cell Adhesion Inhibition by RGD Peptides Linked with a Photoisomerizable Nonnatural Amino Acid.J Southeast Univ. 2001;17:22-26.
Liu LY, Chen ZY, Zhao TH. Synthesis of RGD identical-fork-peptide derivative with inhibitive effecton adhesiveness of advanced metastatic tumor cells.Zhongguo Xinyao Zazhi. 2006;15:1661-1663.
Zhao M, Wang C, Jiang X, Pen S. Synthesis of RGD containing peptides and their bioactivities.Prep Biochem Biotechnol. 2002;32:363-380.
Cao K, Zhao TH, Chen ZY, Gao W, Yang HS, Shi B. The invasive capacity of human lung great cellular xancerous PG cells on reformed basement membrane and inhibition of synthetic peptides.Zhongliu Fangzhi Yanjiu. 2002;29:20-22.
Okroj M, Dobrzaska-Paprocka Z, Rolka K, Bigda J. In vitro and in vivo analyses of the biological activity of RGD peptides towards Ab Bomirski melanoma.Cell Mol Biol Lett. 2003;8:873-884.
Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zanker KS, Dittmar T. Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells.Clin Exp Metastasis. 2005;22:99-106.
Liu YK, Wu WZ, Wu X, Jiang Y, Zhou XD. Liver cancer metastasis and signal transduction.Metastasis and recurrence of hepatocellular carcinoma--basic and clinical studies. Shanghai: Shanghai scientific and technological education public house; 2003;93-104.
Liu YK, Nemoto A, Feng Y, Uemura T. The binding ability to matrix proteins and the inhibitory effects on cell adhesion of synthetic peptides derived from a conserved sequence of integrins.J Biochem. 1997;121:67-74.
Uemura T, Nemoto A, Liu YK. Synthetic peptide derived from a conserved sequence of integrin β subunit. Res.Adv in Biosci & Bioeng. 2000;23:65-83.
Sun JJ, Zhou XD, He JY, Liu YK, Tang ZY. Inhibition of the nude mice liver cancer metastasis and recurrence by beta peptide.Zhonghua Shiyan Waike Zazhi. 2000;17:418-420.
Sun JJ, Zhou XD, Liu YK, Tang ZY, Shi JY, Bao WH, Xue Q. An experimental study on preventing and treating metastasis and recurrence of human liver cancer with anti-adhesive drugs in nude mice.Zhonghua Xiaohua Zazhi. 2000;20:53-54.
Sun JJ, Zhou XD, Liu YK, Tang ZY. An experimental study of the effect of β peptide on liver cancer recurrence and metastasis.Zhonghua Putong Waike Zazhi. 2000;15:27-31.
Sun JJ, Zhou XD, Liu YK, Tang ZY, Sun RX, Zhao Y, Uemura T. Inhibitory effects of synthetic beta peptide on invasion and metastasis of liver cancer.J Cancer Res Clin Oncol. 2000;126:595-600.
Sun DX, Zhang L, Chen XQ. In vitro test of cell proliferation and cytotoxic.General methods of immunologic experiment. Beijing: People’s Military Medical Press; 2000;193.
Knutson JR, Iida J, Fields GB, McCarthy JB. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes.Mol Biol Cell. 1996;7:383-396.
Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, Ma ZC. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues.Int J Cancer. 1996;66:239-243.
Syrigos KN, Karayiannakis AJ. Adhesion molecules as targets for the treatment of neoplastic diseases.Curr Pharm Des. 2006;12:2849-2861.
Jiang CG, Xu HM. Research and application of anti-adhesion therapy in cancer metastasis.Guowai Yixue (Zhongliuxue Fence). 2005;32:31-34.
Okroj M, Dobrzaska-Paprocka Z, Rolka K, Bigda J. In vitro and in vivo analyses of the biological activity of RGD peptides towards Ab Bomirski melanoma.Cell Mol Biol Lett. 2003;8:873-884.
Wang YH, Liu YK, Li WC, Ye SL, Tang ZY. Inhibitory effect of anti-adhesion peptides on invasion/metastasis ability of hepatocellular carcinoma cells.Zhonghua Shiyan Waike Zazhi. 2004;21:1168-1169.
Liu J, Guo SX, Tang JG. Research progress of RGD-peptide for cancer therapy.Guowai Yixue (Zhongliuxue Fence). 2003;30:193-197.
Maeda M, Izuno Y, Kawasaki K, Kaneda Y, Mu Y, Tsutsumi Y, Nakagawa S, Mayumi T. Amino acids and peptides. XXXI. Preparation of analogs of the laminin-related peptide YIGSR and their inhibitory effect on experimental metastasis.Chem Pharm Bull (Tokyo). 1998;46:347-350.
Kaneda Y, Yamamoto Y, Okada N, Tsutsuml Y, Nakagawa S, Kakiuch M, Maeda M, Kawasaki K, Mayumi T. Antimetastatic effect of synthetic Glu-Ile-Leu-Asp-Val peptide derivatives containing D-amino acids.Anticancer Drugs. 1997;8:702-707.
Feng ZH, Huang B, Zhang GM, Li D, Wang HT. Inducement of antitumor-immunity by DC activated by Hsp70-H22 tumor antigen peptide.Chin J Cancer Res. 15:79-85.